Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug3806 | SCTA01 Wiki | 0.71 |
drug3195 | Placebo Wiki | 0.04 |
Name (Synonyms) | Correlation |
---|
Navigate: Correlations HPO
There is one clinical trial.
This is a Phase 3, open-label, multi-center, interventional safety study of REM therapy in participants 12 years of age or older with COVID-19, pneumonia and oxygen supplementation.
Description: The primary endpoint of the study is the proportion of patients with at least one treatment-emergent AESI (hypersensitivity including infusion-related reaction, anaphylactic reaction, acute respiratory failure, hypotension, hepatic toxicity and nephrotoxicity).
Measure: To assess the safety and tolerability of REM use in Hungary in the conditionally approved indication (EMA) Time: 30 daysDescription: Secondary safety endpoint
Measure: The proportion of patients with at least 1 treatment-emergent adverse event Time: 30 daysDescription: Secondary safety endpoint laboratory abnormalities (separately for the following parameters: ALT, AST, INR, HGB, Bilirubin, ALP, Creatinine, eGFR)
Measure: Proportion of patients with treatment-emergent clinical Time: 30 daysDescription: Secondary efficacy endpoint
Measure: Time to recovery (days) Time: 30 daysDescription: Secondary efficacy endpoint
Measure: Time to discharge from hospital (days) Time: 30 daysDescription: Secondary efficacy endpoint
Measure: Number and proportion of patients at prespecified timepoints in each category of the WHO Ordinal Scale for Clinical Improvement Time: 30 daysDescription: Secondary efficacy endpoint - timepoints in each category (Ambient air, Low flow, Medium Flow, High Flow, Non invasive ventilation, Invasive ventilation, ECMO)
Measure: Number and proportion of patients at prespecified in each category Time: 30 daysDescription: Secondary efficacy endpoint
Measure: Proportion of participants with normalization of fever Time: 30 daysDescription: Secondary efficacy endpoint - proportion of participants with normalization of oxygen saturation (>=95%) through Day 10 with 14 days follow-up after the last dose
Measure: Proportion of participants with normalization of oxygen saturation Time: 30 daysDescription: Exploratory endpoints - Number and proportion of patients at prespecified timepoints in each category of the 8-point ordinal scale of disease severity.
Measure: Number and proportion of patients Time: 30 daysDescription: Exploratory endpoints - Proportion of patients with clinically relevant improvement in radiological findings as assessed by the investigator at discharge from hospital
Measure: Proportion of patients with clinically relevant improvement in radiological findings Time: 30 daysDescription: Exploratory endpoints - Proportion of patients with COVID19 complications/remaining symptoms as assessed by the investigator at discharge from hospital
Measure: Proportion of patients with COVID19 complications/remaining symptoms Time: 30 daysDescription: Exploratory endpoints
Measure: Proportion of patients with at least one treatment- or intervention-related adverse event Time: 30 daysAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports